ProfileGDS5678 / 1449711_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 64% 63% 65% 66% 65% 61% 63% 63% 65% 64% 63% 65% 64% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.8840264
GSM967853U87-EV human glioblastoma xenograft - Control 23.7857263
GSM967854U87-EV human glioblastoma xenograft - Control 33.9344965
GSM967855U87-EV human glioblastoma xenograft - Control 44.0353866
GSM967856U87-EV human glioblastoma xenograft - Control 53.8499365
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.7298161
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8564763
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7576263
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.8907765
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8155364
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.7929163
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.8923765
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.8419664
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8598564